What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Disease
Kenji Kabashima mostly deals with Immunology, Immune system, Cell biology, Atopic dermatitis and Inflammation.
His Immunology study frequently intersects with other fields, such as Keratinocyte.
His Immune system study incorporates themes from Melanoma and Lymph.
The study incorporates disciplines such as Cytotoxic T cell, IL-2 receptor, Chemokine, Receptor and Dermis in addition to Cell biology.
His Atopic dermatitis study combines topics from a wide range of disciplines, such as Psoriasis, Internal medicine, Pathogenesis and T helper cell.
His Inflammation study combines topics in areas such as Anatomy and Cutaneous immunity.
His most cited work include:
- Prostaglandin D2 as a mediator of allergic asthma. (672 citations)
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma† (499 citations)
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma† (499 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Immunology, Dermatology, Immune system, Pathology and Atopic dermatitis.
His research in Inflammation, Antigen, Psoriasis, Pathogenesis and Immunoglobulin E are components of Immunology.
His study on Immune system is mostly dedicated to connecting different topics, such as Cell biology.
His Atopic dermatitis study frequently links to other fields, such as Internal medicine.
He most often published in these fields:
- Immunology (53.80%)
- Dermatology (32.08%)
- Immune system (23.93%)
What were the highlights of his more recent work (between 2019-2021)?
- Dermatology (32.08%)
- Atopic dermatitis (21.28%)
- Immune system (23.93%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Dermatology, Atopic dermatitis, Immune system, Immunology and Inflammation.
In his study, Melanoma is strongly linked to Nivolumab, which falls under the umbrella field of Dermatology.
His biological study spans a wide range of topics, including Internal medicine, Randomized controlled trial and Clinical endpoint.
His Immune system research is multidisciplinary, incorporating perspectives in Cell type, Intravital Imaging and Pathology.
His studies in Thymic stromal lymphopoietin, Immunoglobulin E, Filaggrin, Acquired immune system and Pathogenesis are all subfields of Immunology research.
His work carried out in the field of Inflammation brings together such families of science as Dendritic cell, Antibody, Innate lymphoid cell and Cell biology.
Between 2019 and 2021, his most popular works were:
- Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials (51 citations)
- Type 2 immunity in the skin and lungs. (41 citations)
- Type 2 immunity in the skin and lungs. (41 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Disease
His primary scientific interests are in Atopic dermatitis, Immunology, Immune system, Inflammation and Dermatology.
His Atopic dermatitis research includes elements of Internal medicine, Quality of life, Clinical trial and Interleukin 15.
His study in Incidence extends to Immunology with its themes.
His research ties Cytotoxic T cell and Immune system together.
His Inflammation research incorporates themes from Antigen, Antibody, Innate lymphoid cell, In vivo and Histamine.
Kenji Kabashima has included themes like Epidermolysis bullosa acquisita, Spirometry, Pemphigoid and Intravenous Immunoglobulins in his Dermatology study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
